Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Nicotinamide Riboside Chloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 915Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ChromaDex Expands Niagen® IV And Injection Offerings
    ChromaDex Expands Niagen® IV And Injection Offerings

    10 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240910527761/en

    BUSINESSWIRE
    10 Sep 2024
    Share Share
    ChromaDex To Launch IV And Injectable Niagen At Wellness Clinics
    ChromaDex To Launch IV And Injectable Niagen At Wellness Clinics

    16 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240716150746/en

    BUSINESSWIRE
    16 Jul 2024
    Share Share
    ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharma-Grade IV & Inj Niagen
    ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharma-Grade IV & Inj Niagen

    13 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240613823864/en

    BUSINESSWIRE
    13 Jun 2024
    Share Share
    ChromaDex Gets US Orphan, Rare Pediatric Status For NRC In AT
    ChromaDex Gets US Orphan, Rare Pediatric Status For NRC In AT

    07 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240607042855/en

    BUSINESSWIRE
    07 Jun 2024
    Share Share
    ChromaDex wins orphan designation for rare ataxia drug
    ChromaDex wins orphan designation for rare ataxia drug

    07 Jun 2024

    // Justine Ra PHARMACEUTICAL TECHNOLOGY

    https://www.pharmaceutical-technology.com/news/chromadex-wins-orphan-designation-for-rare-ataxia-drug/

    Justine Ra PHARMACEUTICAL TECHNOLOGY
    07 Jun 2024
    Share Share